Ivabradine
FDA-approved product (solution, oral), marketed as Corlanor, Ivabradine Hydrochloride.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Angina pectoris
- Cardiovascular disease
- Congestive heart failure
- Heart failure
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other cardiac preparations
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae33.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ivabradine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Enalapril MaleateExisting use: Cardiovascular disease, Congestive heart failure, Heart failure and 2 more69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ElbasvirExisting use: Chronic hepatitis C virus infection, Viral disease69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- BendroflumethiazideExisting use: Cardiovascular disease, Hypertension68.8% AI-predicted activityagainst M. tuberculosis9 registered studies
- ChlorthalidoneExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 6 more68.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ChlorothiazideExisting use: Cardiovascular disease, Chronic kidney disease, Congestive heart failure and 6 more68.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HaloperidolExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more68.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more68.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- RiociguatExisting use: Hypertension, Idiopathic and/or familial pulmonary arterial hypertension, Pulmonary arterial hypertension and 1 more68.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TrichlormethiazideExisting use: Cardiovascular disease67.9% AI-predicted activityagainst M. tuberculosis1 registered study
- Promazine HydrochlorideExisting use: Psychosis67.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- VandetanibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more67.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydroflumethiazideExisting use: Cardiovascular disease67.7% AI-predicted activityagainst M. tuberculosis1 registered study
Registered studies
A registration describes a study; it does not establish a positive result.
Cardiovascular Effects of Selective I(f)-Channel Blockade
NCT00865917 · start 2008-11
Registered record
- Registry ID
- NCT00865917
- Conditions
- Postural Orthostatic Tachycardia Syndrome
- Interventions
- beta-blocker (Metoprolol); I(f)-blocker (ivabradine); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2008-11
- Completion
- 2010-12
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostural Orthostatic Tachycardia SyndromeInterventionbeta-blocker (Metoprolol); I(f)-blocker (ivabradine); PlaceboPhasePhase 2Registry statusUnknownEffects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals
NCT00825123 · start 2008-10
Registered record
- Registry ID
- NCT00825123
- Conditions
- Central Arterial Pressure
- Interventions
- Ivabradine; Metoprolol; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2008-10
- Completion
- 2011-11-08
- Enrolment
- 2
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCentral Arterial PressureInterventionIvabradine; Metoprolol; PlaceboPhasePhase 4Registry statusTerminatedEfficacy Study of Digoxin & Ivabradine to Treat Heart Failure
NCT01699776 · start 2008-04
Registered record
- Registry ID
- NCT01699776
- Conditions
- Cardiac Failure
- Interventions
- Ivabradine; Digoxin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-04
- Completion
- 2012-02
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiac FailureInterventionIvabradine; DigoxinPhasePhase 4Registry statusCompletedEffects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study
NCT02441218 · start 2006-09
Registered record
- Registry ID
- NCT02441218
- Conditions
- Chronic Heart Failure
- Interventions
- Ivabradine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-09
- Completion
- 2010-04
- Enrolment
- 6,505
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Heart FailureInterventionIvabradine; PlaceboPhasePhase 3Registry statusCompletedEfficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris
NCT00202566 · start 2005-06
Registered record
- Registry ID
- NCT00202566
- Conditions
- Angina Pectoris
- Interventions
- Ivabradine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-06
- Completion
- 2007-10
- Enrolment
- 750
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAngina PectorisInterventionIvabradinePhasePhase 3Registry statusCompleted